secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2021-10-18T23:59:59+00:00
Accession:  0001193125-21-300558
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology CEO Owen Hughes departs; Nadim Ahmed appointed as new President and CEO
--------------------------------------------------------------------------------

- CEO Owen Hughes departs Oct 18, 2021; gets 12 months base salary, pro-rata bonus of $216,507, and accelerated vesting.
- Nadim Ahmed appointed CEO, President, and Board member effective Oct 18; previously President of Hematology at BMS.
- Ahmed receives $600k base salary, $625k sign-on bonus, 2.71M stock options, and performance RSUs.
- Hughes will serve as Strategic Advisor for up to 12 months; noncompetition and nondisclosure covenants apply.
- Company reaffirms Pearl update expected in Q4 2021; no change to pipeline plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/d66778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-300558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer